Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExCIT: Hetrombopag Olamine in Chemotherapy-Induced Thrombocytopenia
NCT07286032Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Part A: Hetrombopag Olamine with Part B: Hetrombopag Olamine vs Placebo (2 arms). Primary endpoints: Maximum plasma concentration of hetrombopag at 6 months, Area under the plasma concentration-time curve of hetrombopag at 6 months and 4 more. Started Apr 2026; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT07286032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286032.